Brain cancer drug Gleostine is no longer available for coverage under Medicare Part D after its seller, Miami-based NextSource Biotechnology, removed it from the program, according to The Wall Street Journal.
The drug, which treats brain cancers including glioblastoma, does not have a generic alternative and can cost as much as $1,000 per capsule, the article said.
In a statement to the Journal, NextSource said it is exploring a new contract with the program and plans to participate again in the future, though it did not specify why the drug's coverage benefits ended Jan. 1.
NextSource also told the publication that Medicare patients meeting certain income criteria have been eligible to receive the drug at no cost since January.